Foundayo vs Zepbound vs the Wegovy Pill: A Woman's Side-by-Side

The short answer

Zepbound, a weekly injection, produced the largest average weight loss in its trial: 20.9% at the top dose. The Wegovy pill reached 13.6% and Foundayo 11.2% at their top doses. Foundayo is the only one of the three you can take with food. For a breastfeeding mother, both pills are labeled "not recommended," while Zepbound's label asks her and her doctor to weigh the benefits.

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

The three side by side

Is Foundayo as strong as Zepbound?

On the trial numbers, no. But these are three separate trials, not a contest. No study has put any two of these drugs against each other.

Foundayo, ATTAIN-1. 3,127 adults with obesity and no diabetes took orforglipron or placebo for 72 weeks. Average weight change was −7.5%, −8.4% and −11.2% across the three doses, against −2.1% on placebo. At the top dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Between 5.3% and 10.3% stopped because of side effects, against 2.7% on placebo¹.

One detail confuses many readers. The trial used an earlier, investigational formulation at 6, 12 and 36 mg. The Foundayo label reports those same arms as the equivalent marketed tablets: 5.5, 9 and 17.2 mg. The label's own table gives −11.1% for the top dose, a slightly different calculation of the same trial².

Zepbound, SURMOUNT-1. 2,539 adults without diabetes, 72 weeks. Average change was −15.0%, −19.5% and −20.9% at 5, 10 and 15 mg, against −3.1% on placebo³.

Wegovy pill, OASIS 4. 307 adults without diabetes took 25 mg oral semaglutide or placebo. At week 64, average change was −13.6% versus −2.2%. Stomach and gut side effects were common: 74.0% against 42.2% on placebo⁵.

Reading across, the injection sits well ahead and the two pills sit closer together. The gap is wide, but only a direct trial could say exactly how wide.

What do the labels say specifically to women?

Hair loss. Both Lilly labels break this out by sex. On Foundayo, hair loss was reported in 7% of women and 0.9% of men, against 3% and 0.7% on placebo². On Zepbound, it was 7.1% of women and 0.5% of men, against 1.3% and 0%⁴. Both labels tie it to weight reduction. The Wegovy label gives a split for the injection (4% of women, 0.9% of men) but not for the tablet⁶. More on this in hair loss on a GLP-1.

Birth control pills. This is where the three differ most. Foundayo's label tells women on oral contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and 30 days after each dose increase². Zepbound's says the same for 4 weeks after starting and after each increase⁴. Because both drugs step up several times, that adds up to months of backup. The Wegovy label carries no such instruction⁶. Non-oral hormonal methods, such as the patch, ring, implant or hormonal IUD, are not expected to be affected by either Lilly drug. The birth control guide has the full calendar.

Breastfeeding. Foundayo's label says it is not recommended for nursing women². The Wegovy tablet label also advises that breastfeeding is not recommended, because an absorption ingredient called SNAC passes into milk and may build up in infants⁶. Zepbound's label is different: there are no data on the breastfed infant, and it asks that the benefits of breastfeeding be weighed against the mother's need for the drug⁴. More detail is in GLP-1s and breastfeeding.

The morning routine

For a mother, the daily routine can matter as much as the trial average.

Foundayo has the simplest routine of the three. The label says to take it once daily, with or without food, swallowed whole². There is no fasting window.

The Wegovy pill asks the most. It must be taken on an empty stomach in the morning with no more than 4 ounces of plain water, and then you wait at least 30 minutes before eating, drinking anything else or taking other pills⁶. That half-hour has to happen before breakfast, every day. The Wegovy pill vs the injection explains why the rule matters.

Zepbound is one injection a week, on the same day, with or without food.

What does each cost without insurance?

Both companies sell direct, and prices were read from their own pages in October 2026. All of these offers run through December 31, 2026.

Foundayo: $149 a month for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9, 14.5 and 17.2 mg. The $299 price on the two top doses requires each refill within 45 days. The regular top-dose price is $349.

Zepbound KwikPen: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg when each refill is bought within 45 days. Otherwise the regular price is $499 for 7.5 mg and $699 for 10 to 15 mg.

Wegovy pill: $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg through NovoCare Pharmacy.

Eligible Medicare patients may pay $50 a month for any of the three through the Medicare GLP-1 Bridge, and with commercial insurance that covers the drug, savings cards can bring the copay as low as $25. The cost guide has the details, and the LillyDirect Foundayo review and NovoCare Pharmacy review walk through ordering.

Who might each suit?

• If you will not inject: either pill. Foundayo if mornings are chaotic, since food doesn't matter. The Wegovy pill if you can protect a 30-minute window and want the pill with the larger average loss in its own trial.
• If the largest average loss matters most: Zepbound, by a clear margin in the trials.
• If you are breastfeeding: neither pill is recommended. Zepbound is a conversation with your doctor, not a yes.
• If you rely on the pill for birth control: the Wegovy pill has no backup instruction. Both Lilly drugs require backup with each dose step.

How solid is this comparison?

Each figure here comes from a large, placebo-controlled trial and an FDA label, which is strong evidence for each drug on its own. The comparison between them is weaker, because no trial has tested any of the three against another. Treat the gap between the shot and the pills as real but approximate, and the small gap between the two pills as uncertain.